Reata Pharmaceuticals CEO and leadership

Warren is the Chairman, Chief Executive Officer, and President of Reata Pharmaceuticals. He has served as our sole CEO, President, and as Chairman of the Board of Directors since our founding in 2002. Prior to founding Reata, Warren served as CEO in a number of health care and information technology start-up enterprises. Warren started his career as an attorney with Johnson & Gibbs, P.C., where he was a partner and Chairman of the Corporate Securities Practice. He received a B.B.A. magna cum laude from the University of Texas at Austin and a J.D. from Southern Methodist University Dedman School of Law.

W 'Chris' Wigley is a Senior VP/Chief Scientific Ofcr:Research at REATA PHARMACEUTICALS INC and VP:Research/Founding Scientist at REATA PHARMACEUTICALS INC. He studied at Gamma Beta Phi Society.

Dawn is Chief Commercial Officer of Reata Pharmaceuticals and leads marketing, market access, sales, training, and commercial operations. She joined Reata in September 2016. Prior to joining Reata, Dawn served as Vice President of Sales with Pharmacyclics, LLC, where she built and led their first hematology national sales organization of sales representatives, division managers, and regional sales directors, and was responsible for the launch of IMBRUVICA in the US and Puerto Rico. Before that, Dawn served as Vice President of Sales & Marketing with McKesson US Pharmaceutical, SKY Pharmaceuticals, and RxPak. She held positions of increasing responsibility within McKesson Corporation, Genentech, Inc., and Bristol-Myers Squibb Company. Dawn holds a B.S. in Biology from Binghamton University.

Colin is Chief Research & Development Officer of Reata Pharmaceuticals and is responsible for the strategic direction of Reata’s research, development, and clinical functions. He leads product development and strategy, clinical trial design and analysis, medical affairs, pharmacovigilance, research, and discovery chemistry. He joined Reata in 2003 as its second employee and was involved with the initial in-licensing activities that resulted in the acquisition of several of Reata’s technologies, including its lead programs. Colin has held various roles of increasing responsibility in Clinical, Regulatory, and Product Development and served as Reata’s Chief Medical Officer for seven years before being appointed to his current role. Colin received a B.S. in chemistry with a specialization in biochemistry and a B.A. in biology from the University of Virginia. He received an M.D. from the University of Texas Southwestern Medical School and an M.B.A. from Southern Methodist University Cox School of Business.

Mr. Soni is currently COO & CFO of Reata Pharmaeuticals managing overall global financial strategy, corporate strategy, business development, IT, Investor Relations, Manufacturing, Quality, Risk Management, project management and Corporate Communications. He is currently board member and Audit committee chair at Arena Pharmaceuticals, Summit Therapeutics and Pulse Biosciences. He is former CFO of Alnylam Pharmaceuticals, Inc where he managed global finance, tax, treasury, procurement, investor relations and corporate communications. He led the buildout of Alnylam’s global financial and commercial operational infrastructure to support its global expansion across multiple geographies and strengthening its balance sheet with over $2.5B ($1.5 B of new capital raise and $1B collaboration deal with REGN). He is former CFO of ARIAD Pharmaceuticals, Inc. He played a vital role in the acquisition of ARIAD by Takeda for over $5.2 billion. He also played important role in strategic review and executing a turnaround for ARIAD. ARIAD focused on discovering, developing and commercializing precision therapies for patients with rare cancers. Mr. Soni managed global Finance & Accounting, Investor Relations, Corporate communications, IT and Facilities department at ARIAD. Before joining Ariad Pharmaceuticals as CFO, Mr. Soni worked at Pharmacyclics from 2012 to 2015. He played a vital role in Pharmacyclics' acquisition by Abbvie for $21 billion. Most recently he worked as Chief Financial Officer and Treasurer at Pharmacyclics where he played a key role in building the company from clinical company to a fully viable global commercial company. Prior to that, Mr. Soni worked at PricewaterhouseCoopers (PwC) for more than 10 years. Most recently, he was in the Life Science and Venture Capital Group of the PwC San Jose office providing assurance services to various public and privately held pharmaceutical and biotech companies. He is a Certified Public Accountant, licensed in the state of California and Chartered Accountant from India.

Warren is the Chairman, Chief Executive Officer, and President of Reata Pharmaceuticals. He has served as our sole CEO, President, and as Chairman of the Board of Directors since our founding in 2002. Prior to founding Reata, Warren served as CEO in a number of health care and information technology start-up enterprises. Warren started his career as an attorney with Johnson & Gibbs, P.C., where he was a partner and Chairman of the Corporate Securities Practice. He received a B.B.A. magna cum laude from the University of Texas at Austin and a J.D. from Southern Methodist University Dedman School of Law.

W 'Chris' Wigley is a Senior VP/Chief Scientific Ofcr:Research at REATA PHARMACEUTICALS INC and VP:Research/Founding Scientist at REATA PHARMACEUTICALS INC. He studied at Gamma Beta Phi Society.

Warren is the Chairman, Chief Executive Officer, and President of Reata Pharmaceuticals. He has served as our sole CEO, President, and as Chairman of the Board of Directors since our founding in 2002. Prior to founding Reata, Warren served as CEO in a number of health care and information technology start-up enterprises. Warren started his career as an attorney with Johnson & Gibbs, P.C., where he was a partner and Chairman of the Corporate Securities Practice. He received a B.B.A. magna cum laude from the University of Texas at Austin and a J.D. from Southern Methodist University Dedman School of Law.